Hisse Senetlerindeki Sıralama
#15445
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Hisse Fiyatı
$9.34
Son senkronizasyon: 2026-08-31
Ticaret BioAge Labs Inc. (BIOA)
B piyasa değeri ile BIOA fiyatı
Piyasa Değeri BioAge Labs Inc.(BIOA)
Piyasa Değeri: $351.70M
September 2026 itibarıyla BioAge Labs Inc. şirketinin piyasa değeri $351.70M. Bu, verilerimize göre BioAge Labs Inc. şirketini dünyanın en değerli 15445th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
BioAge Labs Inc. piyasa değeri geçmişi (2024 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında BIOA
| BIOA’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.327T
|
+1,514,486.04%
|
|
|
|
|
$4.645T
|
+1,320,591.64%
|
|
|
|
|
$4.070T
|
+1,157,209.34%
|
|
|
|
|
$3.785T
|
+1,075,981.05%
|
|
|
|
|
$2.790T
|
+793,224.00%
|
